DBV Technologies
Open
$21.00
Prev. Close
$21.00
High
$21.00
Low
$20.89
Market Snapshot
$686.6M
-4.7
-5.80
$4.15M
117
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
emptyResult
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Recently from Cashu
DBV Technologies: Moving Forward in Innovative Treatments for Food Allergies
DBV Technologies: Advancing Solutions for Food Allergies DBV Technologies is making notable progress in the realm of food allergy treatments, as highlighted by the recent endorsement from analyst Yati…
DBV Technologies Advances Allergy Solutions Amid Market Optimism and Growing Consumer Demand
DBV Technologies Leverages Market Optimism to Propel Allergy Therapeutics Forward DBV Technologies, a leader in the development of innovative immunotherapies for food allergies, stands at a pivotal mo…
DBV Technologies Advances Allergy Treatments with Promising Viaskin Peanut Development
DBV Technologies Sees Progress in Allergy Treatment Development DBV Technologies, a biopharmaceutical company focused on developing treatments for food allergies, continues to make strides in its clin…
DBV Technologies Advances Allergen Immunotherapy with Innovative Viaskin Patch Technology
DBV Technologies: Advancements in Allergen Immunotherapy DBV Technologies is at the forefront of innovation in the field of allergen immunotherapy, leveraging its proprietary Viaskin technology to cre…